Results 81 to 90 of about 4,117 (196)

Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno‐Free Culture Systems

Advanced Healthcare Materials, Volume 15, Issue 34, 11 September 2026.
Advances in cell sources, bioengineering, and manufacturing are reshaping the design of skin substitutes. This review highlights emerging strategies driving skin tissue engineering and discusses their potential to enable safer, reproducible, and clinically accessible skin substitutes for regenerative medicine.
Gilles Lemaître, Marina Trouillas, Tatiana Vinasco‐Sandoval, Cécile Giordano, Alexandre G. Lellouch, Walid Rachidi, Jean‐Jacques Lataillade, Nicolas O. Fortunel   +7 more
wiley   +1 more source

Organ‐Specific Cancer‐Associated Fibroblast Subtypes Across the Digestive System Linked to Cancer Hallmarks

Cancer Science, Volume 117, Issue 9, Page 2496-2508, September 2026.
We integrated 14 single‐cell RNA‐seq datasets and 18 bulk cohorts to define eight CAF subtypes in GI cancers. myCAF1 and myCAF2 promoted immunosuppressive, poor‐prognosis niches, whereas iCAF1 was linked to favorable prognosis and antitumor immunity.
Huaitao Wang, Takashi Semba, Atsuko Yonemura, Hiroshi Naito, Lingfeng Fu, Takuya Tajiri, Masaaki Iwatsuki, Takatsugu Ishimoto   +7 more
wiley   +1 more source

Integrated Immune, Epithelial and Lipid Pathways in NSAID‐Exacerbated Respiratory Disease

Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.
ABSTRACT NSAID‐exacerbated respiratory disease (N‐ERD) is a chronic inflammatory disorder characterized by asthma, chronic rhinosinusitis with nasal polyps and respiratory reactions to cyclooxygenase‐1 inhibiting nonsteroidal anti‐inflammatory drugs (NSAID).
Piotr Szatkowski, Lucyna Mastalerz
wiley   +1 more source

Antisense oligonnucleotide treatment of COL7A1 causes non-specific splice modifications

, 2018
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited disease caused by bi‐allelic mutations in the COL7A1, which results in severe blistering of the skin and mucous membranes. Current therapies treat the symptoms but not the disease.
West, K.A., Wilton, S.D., Fletcher, S.
core  

Evolving Pathology of Anaplastic Thyroid Carcinoma: Integrating Morphology, Immunohistochemistry, and Molecular Insights

Cancer Science, Volume 117, Issue 8, Page 2029-2039, August 2026.
Schematic overview of progression from differentiated thyroid carcinoma (DTC) to anaplastic thyroid carcinoma (ATC). ATC primarily develops via two pathways: the BRAF p.V600E‐mutated papillary thyroid carcinoma (PTC) pathway and the RAS‐mutated pathway. The origin and progression of BRAF/RAS‐wildtype ATC remain unclear.
Toru Odate, Tetsuo Kondo
wiley   +1 more source

Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs

, 2020
Genome editing represents a promising strategy for the therapeutic correction of COL7A1 mutations that cause recessive dystrophic epidermolysis bullosa (RDEB).
Webber, Beau R., Osborn, Mark J., Eide, Cindy R., Nielsen, Sarah C., Liu, David R., Dabelsteen, Sally, Blazar, Bruce R., Knipping, Friederike, Chen, Weili, Riddle, Megan J., Xia, Lily, Newby, Gregory A., Wandall, Hans H., Tolar, Jakub, McElroy, Amber N.   +14 more
core   +1 more source

Revertant Mosaicism Due to a Second-Site Mutation in COL7A1 in a Patient with Recessive Dystrophic Epidermolysis Bullosa [PDF]

, 2010
Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.
Cuadrado-Corrales, Natividad, Marta Garcia, Maria J. Escamez, Natividad Cuadrado-Corrales, Escamez, Maria J., Jonkman, Marcel F., García Díez, Marta, Escámez Toledano, María José, Azon, Antoni, Río Nechaevsky, Marcela del, Del Rio, Marcela, Garcia, Marta, Antoni Azon, Pasmooij, Anna M. G., Nijenhuis, A. Miranda, A. Miranda Nijenhuis, Marcela Del Rio, Marcel F. Jonkman, Anna M.G. Pasmooij   +18 more
core   +1 more source

Identification of COL7A1 as a prognostic biomarker in lung squamous cell carcinoma

, 2022
Abstract The Collagen Type VII Alpha 1 Chain (COL7A1) is associated with a variety of cancers, however, COL7A1 gene expression in human lung squamous cell carcinoma (LUSC) and its prognostic value have not been well studied. In this study, we used bioinformatics database to analyze the relationship between COL7A1 expression and survival in LUSC
Weihao Song, Ling Li, Jinyu Zhang, Shuang Wang, Zhe Leng, Ran Lu, Chenglin Li, Xiaoran Ma, Tiantian Wang, Xihui Jia   +9 more
openaire   +1 more source

Three cases of de novo dominant dystrophic epidermolysis bullosa associated with the mutation G2043R in COL7A1

, 2001
In the absence of a positive family history, it is often difficult to determine whether a single case of mild-to-moderately severe dystrophic epidermolysis bullosa (DEB) represents autosomal recessive or de novo dominant disease.
Mellerio, J E, Mohammedi, R, McGrath, J A, Ashton, G H S, Salas-Alanis, J C, Eady, R A J, Denyer, J E, Wessagowit, V   +7 more
core   +1 more source

Dystrophic Epidermolysis Bullosa

Journal of Nepal Medical Association, 2018
Epidermolysis bullosa is a rare inherited blistering disease with an incidence of 8-10 per million live births. Dystrophic epidermolysis bullosa is a type of epidermolysis bullosa caused by mutation in type VII collagen, COL7A1.
Randhir Sagar Yadav, Amar Jayswal, Shumneva Shrestha, Sanjay Kumar Gupta, Upama Paudel   +4 more
doaj   +1 more source